0000000000423231

AUTHOR

Audrey Nosbaum

0000-0003-2281-9052

Residents’corner December 2013. Editorial: what's new this month?

ejd.2013.2259 Auteur(s) : Rubeta NH Matin1 rnhmatin@doctors.org.uk, Alejandro Martin-Gorgojo2 alejandromartingorgojo@aedv.es, Ana Rita Travassos3 ritatravassos@gmail.com, Kristina Buder4 Buder_K@ukw.de, Helena Clayton5 helena.clayton@chuv.ch, Audrey Nosbaum6 NosbaumA@derm.ucsf.edu 1 Department of Dermatology, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, United Kingdom 2 Dermatology Department, Clinical University Hospital of Valencia, University of Valencia, Av Blasco Ibanez 17, 46010 [...]

research product

Residents'corner April 2014. Editorial: what's new this month?

In this issue of the European Journal of Dermatology, Bircher et al.[1] revisit tolerance induction in drug hypersensitivity reactions, which is a controversial issue, particularly in delayed hypersensitivity reactions. Drug hypersensitivity may present as a mild, moderate or severe life-threatening reaction, becoming a problem for many patients when the offending drug is essential (and even irreplaceable).Determining which drug is responsible for the reaction may be challenging, especially in multiple [...]

research product

Residents'corner February 2014. Editorial: What's new this month?

In this issue of the EJD, two articles shed light on sun-tanning behaviour in southern Europe [1, 2] that will be discussed here. We also critically review an article by Stockfleth et al. [4] who propose the ‘maximum lesion count’ as a new parameter for efficacy assessment of field-directed therapy for actinic keratoses. Last but not least, the publication of Mailhol et al. [5] on food allergies in children with atopic dermatitis will be reviewed.Skin cancer prevention is an important aspect [...]

research product

Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France

Background One of the major reasons to stop antibiotic prophylaxis (AP) to prevent infective endocarditis (IE) in the United Kingdom but not in the rest of the world was that it would result in more deaths from fatal adverse drug reactions (ADRs) than the number of IE deaths. The main aim of this study was to quantify and describe the ADRs with amoxicillin or clindamycin for IE AP. The second aim was to infer a crude incidence of anaphylaxis associated with amoxicillin for IE AP. Material and Methods The Medical Dictionary for Regulatory Activities (MedDRA) was used to group ADRs for IE AP using the broad Standardized MedDRA Queries “Anaphylactic reaction, Amoxicillin, Clindamycin, Clostrid…

research product